Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells

EGFR/HER2 are frequently expressed in MPM tissues, however, no studies have shown the clinical benefit of using EGFR/HER2-targeting drugs in patients with malignant pleural mesothelioma (MPM). It was reported that the tyrosine kinase inhibitor (TKI) lapatinib enhanced trastuzumab-mediated antibody-d...

Descripción completa

Detalles Bibliográficos
Autores principales: OKITA, RIKI, SHIMIZU, KATSUHIKO, NOJIMA, YUJI, YUKAWA, TAKURO, MAEDA, AI, SAISHO, SHINSUKE, NAKATA, MASAO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722889/
https://www.ncbi.nlm.nih.gov/pubmed/26503698
http://dx.doi.org/10.3892/or.2015.4314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722889/
https://www.ncbi.nlm.nih.gov/pubmed/26503698
http://dx.doi.org/10.3892/or.2015.4314

Ejemplares similares